Efficacy and safety of adjuvant targeted immunotherapy for hepatocellular carcinoma with high recurrence risks after hepatectomy

Table 6 Surgical and perioperative data of 372 participants on follow-up, n (%)/mean ± SD/median (interquartile rage)

	PSM before (n = 372)			PSM after (n = 176)
	ATG (n = 88)	SG (n = 284)	P value	ATG (n = 88)	SG (n = 88)	P value
Surgical methods			0.544			0.114
Laparoscopy	16 (18.2)	58 (20.4)		16 (18.2)	23 (26.1)
Open	68 (77.3)	205 (72.2)		68 (77.3)	56 (63.6)
Anatomic resection			0.013			0.88
No	42 (47.7)	95 (33.5)		42 (47.7)	41 (46.6)
Yes	46 (52.3)	189 (66.5)		46 (52.3)	47 (53.4)
Tumor clinical typing			0.273			0.393
Nodular fusion	7 (8)	16 (5.6)		7 (8)	5 (5.7)
Nodular	48 (54.5)	179 (63)		48 (54.5)	58 (65.9)
Chunky	19 (21.6)	39 (13.7)		19 (21.6)	13 (14.8)
Lumpy	12 (13.6)	46 (16.2)		12 (13.6)	12 (13.6)
Diffuse	2 (2.3)	4 (1.4)		2 (2.3)	0 (0)
Tumor margin (cm)			0.339			0.344
< 1	34 (38.6)	94 (33.1)		34 (38.6)	28 (31.8)
≥ 1	54 (61.4)	190 (66.9)		54 (61.4)	60 (68.2)
Transfusion			0.112			0.202
No	72 (81.8)	251 (88.4)		72 (81.8)	78 (88.6)
Yes	16 (18.2)	33 (11.6)		16 (18.2)	10 (11.4)
Pringle maneuver application			0.945			0.289
No	52 (59.1)	169 (59.5)		52 (59.1)	45 (51.1)
Yes	36 (40.9)	115 (40.5)		36 (40.9)	43 (48.9)
Surgical time (minutes)	254.5 ± 110.2	265.3 ± 113.5	0.43	254.5 ± 110.2	276.8 ± 128.4	0.218
Day of hospitalization (days)	15.4 ± 4.7	15.7 ± 4.5	0.659	15.4 ± 4.5	15.7 ± 4.8	0.661
Blood loss (mL)	275.0 (200.0-500.0)	300.0 (187.5-500.0)	0.148	300.0 (187.5-500.0)	200.0 (100.0-425.0)	0.127
Red blood cell transfusion (mL)	0.0 (0.0-0.0)	0.0 (0.0-0.0)	0.055	0.0 (0.0-0.0)	0.0 (0.0-0.0)	0.176
Plasma transfusion (mL)	0.0 (0.0-0.0)	0.0 (0.0-0.0)	0.253	0.0 (0.0-0.0)	0.0 (0.0-0.0)	0.374
Number of Pringle maneuver time	0.0 (0.0-1.0)	0.0 (0.0-1.0)	0.828	0.0 (0.0-1.0)	0.0 (0.0-1.0)	0.42
Pringle maneuver time (minutes)	0.0 (0.0-20.0)	0.0 (0.0-15.0)	0.933	0.0 (0.0-20.0)	0.0 (0.0-20.2)	0.21

PSM: Propensity score matching; ATG: Adjuvant therapy group; SG: Surgery-alone group.